Laurus Labs' Q1 FY 2026-27 Quarterly Results

Result Summary

• Laurus Labs Ltd reported a 11.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 28.8%.
• Its expenses for the quarter were up by 6.3% QoQ and 14.6% YoY.
• The net profit increased 28.4% QoQ and increased 123.9% YoY.
• The earnings per share (EPS) of Laurus Labs Ltd stood at 6.8 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Laurus Labs Ltd is a prominent Indian pharmaceutical company primarily involved in the research, development, and manufacturing of active pharmaceutical ingredients (APIs) as well as finished dosage forms and biotechnology products. The company operates in the pharmaceutical sector, focusing on therapeutic areas such as antiretrovirals, oncology, cardiovascular, antidiabetic, and anti-inflammatory drugs. Laurus Labs has been known to invest significantly in research and development to expand its product portfolio and improve its manufacturing capabilities. Recent developments or specific strategic initiatives were not provided in the data.

Revenue

During Q1FY27, Laurus Labs Ltd reported a total income of ₹2035.49 crores, marking an increase from the previous quarter's ₹1823.37 crores and the corresponding quarter of the previous year at ₹1580.00 crores. This reflects a quarter-over-quarter growth of 11.6% and a year-over-year growth of 28.8%. The increase in total income suggests growth in the company's revenue streams, potentially driven by higher sales volumes, expanded market reach, or new product introductions. The revenue growth reflects the company's ability to enhance its market presence and capitalize on its product offerings in the pharmaceutical industry.

Profitability

The profitability of Laurus Labs Ltd is reflected in its profit before tax, which stood at ₹481.36 crores for Q1FY27, up from ₹361.37 crores in Q4FY26 and ₹224.22 crores in Q1FY26. This represents a quarter-over-quarter increase of 33.2% and a year-over-year increase of 114.7%. The tax expense for the quarter was ₹119.37 crores, compared to ₹79.46 crores in the previous quarter and ₹63.14 crores in the same quarter last year. The profit after tax for Q1FY27 was ₹362.07 crores, an increase from ₹282.09 crores in Q4FY26 and ₹161.68 crores in Q1FY26, showcasing a quarter-over-quarter growth of 28.4% and a year-over-year growth of 123.9%. The earnings per share for the period was ₹6.80, compared to ₹5.17 in the previous quarter and ₹3.02 in the same quarter the previous year, indicating a quarter-over-quarter growth of 31.5% and a year-over-year growth of 125.2%. These figures suggest an improvement in the company's profitability metrics over the periods compared.

Operating Metrics

The total expenses for Laurus Labs Ltd in Q1FY27 were ₹1554.13 crores, up from ₹1462.00 crores in Q4FY26 and ₹1355.78 crores in Q1FY26, reflecting a quarter-over-quarter increase of 6.3% and a year-over-year increase of 14.6%. The rise in expenses is an important factor to consider alongside revenue growth, as it impacts the overall profitability margins. The company's ability to manage expenses while increasing revenue indicates operational efficiency. The data provided does not include specific operating metrics such as operating margin, inventory turnover, or other ratios typically used to gauge operational performance. However, the observed increase in expenses is proportionately less than the increase in total income, which could infer a favorable impact on the cost structure and operational efficiency of the company.